Registry of Asthma Patients Initiating DUPIXENT®
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.
Phase
—
Status
Completed
Study type
Observational
Enrollment
718actual
Sites
128
Countries
Canada, Denmark, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-03-02 | actual | When the study began enrolling |
| Primary completion | 2026-04-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-27 | actual | The whole study's end, after follow-up |
| First posted | 2020-02-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Intervention
- Drug: DUPIXENT® — also filed as dupilumab, REGN668, SAR231893
Primary outcomes
what the primary-completion date above is the date OFDemography
measured At Baseline
Baseline Characteristics
measured At Baseline
Publications
- PMID 42060163 — linked by the registry
- PMID 36626107 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed